Quick Answer
Cartesian Therapeutics, Inc. reported Stockholders Equity of -$126.24 million for fiscal year 2025.
Cartesian Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$126.24M | -1755.9% |
| 2024 | -$6.80M | +98.5% |
| 2023 | -$440.18M | -569.1% |
| 2022 | $93.83M | +316.6% |
| 2021 | $22.52M | +225.1% |
| 2020 | -$18.01M | -314.4% |
| 2019 | $8.40M | +255.0% |
| 2018 | -$5.42M | -110.5% |
| 2017 | $51.81M | -5.7% |
| 2016 | $54.96M | +147.2% |
| 2015 | -$116.49M | -32.7% |
| 2014 | -$87.75M | -26.3% |
| 2013 | -$69.46M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$35.84M | -4866.5% | -1318.4% |
| June 30, 2025 | -$2.53M | +97.5% | +88.4% |
| March 31, 2025 | -$21.79M | +81.3% | -220.3% |
| December 31, 2024 | -$6.80M | +98.5% | -1004.5% |
| September 30, 2024 | $752.0K | -98.8% | +100.7% |
| June 30, 2024 | -$101.46M | -255.0% | +13.1% |
| March 31, 2024 | -$116.80M | -256.6% | +73.5% |
| December 31, 2023 | -$440.18M | -569.1% | -829.6% |
- Cartesian Therapeutics, Inc. showed a decrease of -1755.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Cartesian Therapeutics, Inc.’s stockholders equity has declined by 81.7% (from -$69.46 million to -$126.24 million).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: